Taysha Gene Therapies Statistics
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
4.43+0.04 (+0.91%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Pre-market: 4.41 -0.45%
Taysha Gene Therapies by the numbers
Taysha Gene Therapies has a market capitalization of $1.44 billion based on 325.83M shares outstanding. With trailing EPS of $-0.41, Taysha Gene Therapies is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 20.5% below its 50-day average and 18.6% below its 200-day average.
Average daily trading volume is 3.25M shares, or about $14.4 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
TSHA valuation vs. peer median
| Metric | TSHA | Peer median | Difference |
|---|---|---|---|
| Market cap | $1.44B | $1.36B | +6% |
| Avg. volume | 3.25M | 505.63K | +542% |
Peer median across 8 companies: MAZE, INBX, IMCR, COAG, REPL, IMTX, VOR, MESO.
Valuation
- Market cap
- $1.44B
- EPS (TTM)
- $-0.41
- Shares outstanding
- 325.83M
Price and trading
- Previous close
- 4.39
- Open
- 4.33
- Day range
- 4.27 – 4.46
- 52-week range
- 3.69 – 7.30
- 52-week change
- -6.14%
- Beta
- —
- Volume
- 3.76M
- Average volume
- 3.25M
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 3, 2026
Additional statistics
- Market Cap
- 1.44B
- Forward Pe
- -9.58
- Eps
- -0.41
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 7.30
- Week52 Low
- 3.69
- Avg Volume
- 3.25M
- Shares Outstanding
- 325.83M
- Ma50
- 5.57
- Ma200
- 5.44
- Earnings Date
- Nov 3, 2026
- Pct From52w High
- -39.32%
- Pct From52w Low
- 19.96%